Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
VU534
Cat. No.:
0225LY-0764
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
VU534 is a dual inhibitor of sEH and FAAH that also acts as a NAPE-PLD agonist (EC50: 0.30 μM); it is typically applied in studies related to cardiometabolism.
Synonym:
923509-20-0; N-(5,7-dimethyl-1,3-benzothiazol-2-yl)-1-(4-fluorobenzenesulfonyl)piperidine-4-carboxamide; N-(5,7-dimethyl-1,3-benzothiazol-2-yl)-1-(4-fluorophenyl)sulfonylpiperidine-4-carboxamide; N-(5,7-dimethylbenzo[d]thiazol-2-yl)-1-((4-fluorophenyl)sulfonyl)piperidine-4-carboxamide
CAS No.:
923509-20-0
Compound CID:
16831625
Formula:
C21H22FN3O3S2
Formula Weight:
447.55
Specification
Targets&IC50:
FAAH: 1.2 μM; NAPE-PLD: 0.30 μM(EC50); sEH: 1.2 μM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
VU534 can be used in neuroscience research to investigate the selective modulation of potassium channels and their impact on neural excitability.
Library Information
Target:
FAAH; Phospholipase; Epoxide hydrolase
Receptor:
PLD; FAAH; sEH
Pathways:
Metabolism; Neuronal signaling
Plate Number:
AOCL-10
Plate Location:
g11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
6.25 mg/mL; 13.96 mM
